No Prescription |
 |
 | ||
|
Volmax |
|
| ||
No Prescription » Prescription Drugs 17 » Volmax Product Origin: EU (Turkey)This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.Bronchodilator to treat reversible airway obstruction due to asthma.Prevent bronchospasm associated with chronic bronchitis pulmonary emphysema and chronic obstructive pulmonary disorder.Oral albuterol sulfate (salbuterol) belongs to a class of antiasthmatic agents called sympathomimetic bronchodilators. It is used to treat and prevent bronchospasm in patients with reversible obstructive airway disease and exercise-induced bronchospasm. Albuterol sulfate facilitates breathing by stimulating certain receptors in the lungs which causes relaxation of the smooth muscle in the lungs Buy Volmax and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Volmax: Product Type: Prescription Drugs 17 Volmax/Ventolin ( Generic Salbutamol ) Volmax/Ventolin (Generic Salbutamol) Generic Salbutamol 4mg Generic Salbutamol Volmax/Ventolin
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
